For Institutions
About
Wall Street analysts have revised ratings and price targets for several U.S.-listed companies. Notable changes include Cummins' target raised to $580 from $485, Lockheed Martin's to $600 from $520, and Moog's to $300 from $225. Other companies like Rocket Lab and Woodward also saw significant target increases. Conversely, Acadia Healthcare and Adobe experienced target cuts. This summary reflects the latest research actions reported by Reuters.
Lockheed Martin Corporation has successfully completed the first flight test of its Next-Generation Short-Range Interceptor (NGSRI), a potential replacement for the Stinger missile. Conducted at the U.S. Army White Sands Missile Range, the test validated the interceptor’s performance and marked a significant milestone. The NGSRI is designed to counter threats from unmanned aerial systems and aircraft, reportedly doubling the capability of the legacy system. The project advanced from concept to flight in just 26 months, utilizing advanced technologies like AI and machine learning.
Bernstein analyst Courtney Breen has maintained a Buy rating on Gilead Sciences (GILD) with a price target of $135.00. Breen, who covers the Healthcare sector, has an average return of 18.9% and an 84.62% success rate on recommended stocks. Additionally, J.P. Morgan's Chris Schott also issued a Buy rating for Gilead today, while RBC Capital maintained a Hold rating on January 8.
Johnson & Johnson will present 11 abstracts on its neuropsychiatry portfolio at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) from January 12-15, 2026, in Nassau, Bahamas. The presentations will include Phase 3 data on CAPLYTA® for major depressive disorder and analyses of SPRAVATO® for treatment-resistant depression. Additional research on novel mechanisms and AI-driven precision medicine will also be showcased. Results will be shared during poster sessions on January 14 and 15, 2026.
Global drugmakers are increasing U.S. manufacturing and stockpiling inventory in response to a potential 100% tariff on imported medicines. Companies like Pfizer, Eli Lilly, and Johnson & Johnson are committing billions to expand U.S. operations and secure tariff exemptions. Pfizer plans a $70 billion investment, while AstraZeneca and Roche are investing $50 billion each. Other firms, including Novartis and Sanofi, are also making significant investments to mitigate supply-chain risks and reassure investors amid tariff threats.
